Yaman Lu
Overview
Explore the profile of Yaman Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Markovic M, Yeapuri P, Namminga K, Lu Y, Saleh M, Olson K, et al.
NeuroImmune Pharm Ther
. 2024 Feb;
1(1):43-50.
PMID: 38407500
Background: Pharmacological approaches that boost neuroprotective regulatory T cell (Treg) number and function lead to neuroprotective activities in neurodegenerative disorders. Objectives: We investigated whether low-dose interleukin 2 (IL-2) expands Treg...
2.
Yeapuri P, Machhi J, Lu Y, Abdelmoaty M, Kadry R, Patel M, et al.
Mol Neurodegener
. 2023 Dec;
18(1):97.
PMID: 38111016
Background: Regulatory T cells (Tregs) maintain immune tolerance. While Treg-mediated neuroprotective activities are now well-accepted, the lack of defined antigen specificity limits their therapeutic potential. This is notable for neurodegenerative...
3.
Abdelmoaty M, Yeapuri P, Machhi J, Lu Y, Namminga K, Kadry R, et al.
NeuroImmune Pharm Ther
. 2023 Nov;
2(3):317-330.
PMID: 38023614
Objectives: To evaluate the linkage between age and deficits in innate and adaptive immunity which heralds both Alzheimer's disease (AD) onset and progression. The pathobiological events which underlie and tie...
4.
Olson K, Abdelmoaty M, Namminga K, Lu Y, Obaro H, Santamaria P, et al.
Transl Neurodegener
. 2023 May;
12(1):26.
PMID: 37217980
Background: The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer's disease. The safety, tolerability, and mechanisms of...
5.
Yeapuri P, Olson K, Lu Y, Abdelmoaty M, Namminga K, Markovic M, et al.
J Control Release
. 2022 Jun;
348:951-965.
PMID: 35738463
Transformation of CD4+ T cell effector to regulatory (Teff to Treg) cells have been shown to attenuate disease progression by restoring immunological balance during the onset and progression of neurodegenerative...
6.
Machhi J, Yeapuri P, Markovic M, Patel M, Yan W, Lu Y, et al.
ACS Chem Neurosci
. 2022 Mar;
13(8):1232-1244.
PMID: 35312284
Alzheimer's disease (AD) is the most common neurodegenerative disorder. Pathologically, the disease is characterized by the deposition of amyloid beta (Aβ) plaques and the presence of neurofibrillary tangles. These drive...
7.
Machhi J, Yeapuri P, Lu Y, Foster E, Chikhale R, Herskovitz J, et al.
J Neuroinflammation
. 2021 Nov;
18(1):272.
PMID: 34798897
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by pathological deposition of misfolded self-protein amyloid beta (Aβ) which in kind facilitates tau aggregation and neurodegeneration. Neuroinflammation is accepted...
8.
Olson K, Namminga K, Lu Y, Schwab A, Thurston M, Abdelmoaty M, et al.
EBioMedicine
. 2021 May;
67:103380.
PMID: 34000620
Background: Neuroinflammation plays a pathogenic role in Parkinson's disease (PD). Immunotherapies that restore brain homeostasis can mitigate neurodegeneration by transforming T cell phenotypes. Sargramostim has gained considerable attention as an...
9.
Olson K, Namminga K, Lu Y, Thurston M, Schwab A, de Picciotto S, et al.
Biomaterials
. 2021 Apr;
272:120786.
PMID: 33839625
Restoring numbers and function of regulatory T cells (Tregs) is a novel therapeutic strategy for neurodegenerative disorders. Whether Treg function is boosted by adoptive cell transfer, pharmaceuticals, or immune modulators,...
10.
Olson K, Namminga K, Schwab A, Thurston M, Lu Y, Woods A, et al.
Neurotherapeutics
. 2020 Jul;
17(4):1861-1877.
PMID: 32638217
Loss of dopaminergic neurons along the nigrostriatal axis, neuroinflammation, and peripheral immune dysfunction are the pathobiological hallmarks of Parkinson's disease (PD). Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been successfully tested for...